LAPATINIB DITOSYLATE

Search structure
Trade Names:
Synonyms:
Status: Approved (2007)
Entry Type: Small molecule
Molecule Category: Salt
UNII: G873GX646R
Parent Compound: LAPATINIB

Structure
InChI Key XNRVGTHNYCNCFF-UHFFFAOYSA-N
Smile CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1.O
InChI
InChI=1S/C29H26ClFN4O4S.2C7H8O3S.H2O/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19;2*1-6-2-4-7(5-3-6)11(8,9)10;/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35);2*2-5H,1H3,(H,8,9,10);1H2

Physicochemical Descriptors

Property Name Value
Molecular Formula C43H44ClFN4O11S3
Molecular Weight 943.49
AlogP 6.14
Hydrogen Bond Acceptor 8.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 11.0
Polar Surface Area 106.35
Molecular species NEUTRAL
Aromatic Rings 5.0
Heavy Atoms 40.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Epidermal growth factor receptor erbB1 inhibitor DailyMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase EGFR family
- 3-124 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Breast Neoplasms 4 D001943 FDA
Breast Neoplasms 4 D001943 ClinicalTrials
Breast Neoplasms, Male 3 D018567 ClinicalTrials
Squamous Cell Carcinoma of Head and Neck 2 D000077195 ClinicalTrials
Urinary Bladder Neoplasms 2 D001749 ClinicalTrials
Pancreatic Neoplasms 2 D010190 ClinicalTrials
Endometrial Neoplasms 2 D016889 ClinicalTrials
Hypopharyngeal Neoplasms 2 D007012 ClinicalTrials
Urinary Bladder Neoplasms 2 D001749 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 2 D064129 ClinicalTrials
Oropharyngeal Neoplasms 2 D009959 ClinicalTrials
Gliosarcoma 2 D018316 ClinicalTrials
Thyroid Neoplasms 1 D013964 ClinicalTrials
Head and Neck Neoplasms 1 D006258 ClinicalTrials
Central Nervous System Neoplasms 1 D016543 ClinicalTrials
Lymphoma 1 D008223 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Gastrointestinal disorders
17.66
General disorders and administration site conditions
14.9
Skin and subcutaneous tissue disorders
13.85
Nervous system disorders
7.91
Respiratory, thoracic and mediastinal disorders
5.19
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
4.37
Infections and infestations
4.13
Investigations
3.81
Vascular disorders
3.51
Metabolism and nutrition disorders
3.47
Cardiac disorders
3.28
Injury, poisoning and procedural complications
3.11
Musculoskeletal and connective tissue disorders
2.98

Cross References

Resources Reference
ChEBI 49603
ChEMBL CHEMBL1201179
FDA SRS G873GX646R
Guide to Pharmacology 5692
KEGG D08108
PDB FMM
PubChem 11557040
SureChEMBL SCHEMBL4926017
ZINC ZINC01550477
CONTENTS